Decreased tumstatin-mRNA is associated with poor outcome in patients with NSCLC
| Autor: | Yi-Qin Luo, Wen Hu, Jian-Ping Du, Li-Juan Yao, Zhou Ming, Liang Zhao, Hang Dong, Shuang-Zheng Wu |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Collagen Type IV
Male Oncology medicine.medical_specialty Lung Neoplasms Transcription Genetic Tumstatin Angiogenesis Clinical Biochemistry CD34 Down-Regulation Kaplan-Meier Estimate Biology Autoantigens Biochemistry Disease-Free Survival Downregulation and upregulation Carcinoma Non-Small-Cell Lung Internal medicine Genetics Carcinoma medicine Humans RNA Messenger Molecular Biology Aged Proportional Hazards Models Messenger RNA Proportional hazards model Cell Biology Middle Aged Prognosis medicine.disease Microvessels Multivariate Analysis Immunology Female Immunostaining |
| Zdroj: | IUBMB Life. 64:423-431 |
| ISSN: | 1521-6543 |
| DOI: | 10.1002/iub.1016 |
| Popis: | Tumstatin is a candidate tumor suppressor that plays an important role in tumor growth and angiogenesis. The purpose of this study was to evaluate the correlation between tumstatin-mRNA expression and the clinicopathologic characteristics, tumor angiogenesis, outcome of patients with non-small cell lung cancer (NSCLC). Specimens from 68 patients with NSCLC were recruited in this study. Tumstatin-mRNA expression and protein level in tumor tissues were quantified respectively by quantitative RT-PCR and ELISA. Microvessel density (MVD) was determined by CD34 immunostaining. The correlation of tumstatin-mRNA expression levels with clinicopathologic variables, tumor angiogenesis, and prognosis was analyzed. Tumstatin-mRNA expression levels were decreased in tumor. Tumstatin-mRNA expression level was significantly correlated with its protein level in tumor (r = 0.562; P = 0.001). Tumstatin-mRNA expression levels in poorly differentiated tumor tissues were significantly lower than in well-differentiated tumor tissues (P < 0.004). Furthermore, tumor tumstatin-mRNA expression were also significantly related to tumor pathologic stage (P = 0.032) and MVD (r = -0.77, P < 0.0001). Overall survival (OS) and disease-free survival (DFS) analysis indicated that NSCLC patients with low tumstatin-mRNA expression had poorer OS and DFS than those with high expression (P = 0.015 and 0.037; respectively). Multivariable Cox regression analysis revealed that the tumstatin-mRNA expression could be an independent prognostic indicators in both DFS and OS. Tumstatin-mRNA expression levels are down-regulated in NSCLC tissues. Tumstatin-mRNA expression level correlates with prognosis, which suggests that tumstatin-mRNA is a new potential independent marker of favorable prognosis in NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text